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Abstract: The Mediterranean diet is associated with a lower incidence of atherosclerosis, 
cardiovascular disease, neurodegenerative diseases and certain types of cancer. The 
apparent health benefits have been partially ascribed to the dietary consumption of virgin 
olive oil by Mediterranean populations. Much research has focused on the biologically 
active phenolic compounds naturally present in virgin olive oils to aid in explaining 
reduced mortality and morbidity experienced by people consuming a traditional 
Mediterranean diet. Studies (human, animal, in vivo and in vitro) have demonstrated that 
olive oil phenolic compounds have positive effects on certain physiological parameters, 
such as plasma lipoproteins, oxidative damage, inflammatory markers, platelet and cellular 
function, antimicrobial activity and bone health. This paper summarizes current knowledge 
on the bioavailability and biological activities of olive oil phenolic compounds.  
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activator inhibitor-1; ROS, reactive oxygen species; sICAM-1, soluble intercellular 
molecules; sVCAM-1, soluble vascular adhesion molecules; Tau, microtubule-associated 
protein; TC, total cholesterol; TG, triglyceride; TXB2, thromboxane B2 
 
1. Introduction  
A lower prevalence of non-communicable diseases such as cardiovascular disease and certain types 
of cancers have been demonstrated in countries residing in the Mediterranean region in comparison to 
other parts of the world [1–9]. This lowered incidence has been partially attributed to the regular 
intake of virgin olive oil as part of a traditional Mediterranean diet [3,5,9,10–17]. Dietary consumption 
of virgin olive oil in a Mediterranean diet typically ranges between 25–50 mL per day [18].  
Virgin olive oil is produced from the first and second pressings of the olive fruit by the cold-
pressing method (where no chemicals and only a small amount of heat are applied) and is composed of 
a glycerol fraction (making up 90–99% of the olive fruit) and a non-glycerol or unsaponifiable fraction 
(making up 0.4–5% of the olive fruit) which contains phenolic compounds  [19]. Historically, the 
beneficial health effects of virgin olive oil intake were attributed to the glycerol fraction with its high 
concentration of monounsaturated fatty acids (MUFAs) (particularly oleic acid) [19]. However, several 
seed oils (including sunflower, soybean, and rapeseed) containing high quantities of MUFAs are 
ineffective in beneficially altering chronic disease risk factors [20,21]. Therefore, a substantial number 
of investigations examining the biological actions of olive oil phenolic compounds in the 
unsaponifiable fraction have been conducted. In this paper, the term virgin olive oil will be used to 
describe both extra virgin and virgin olive oil. 
Studies conducted thus far (including human, animal, in vivo and in vitro) have demonstrated that 
olive oil phenolic compounds have positive effects on various physiological biomarkers, implicating 
phenolic compounds as partially responsible for health benefits associated with the Mediterranean 
diet  [3,5,22–27]. Furthermore, olive oil phenolic compounds have been shown to be highly 
bioavailable, reinforcing their potential health promoting properties [28–33].  
The phenolic fraction of virgin olive oil is heterogeneous, with at least 36 structurally distinct 
phenolic compounds identified. Variation in the phenolic concentration exists between differing virgin 
olive oils due to numerous factors including: variety of the olive fruit [34–42], region in which the 
olive fruit is grown [37], agricultural techniques used to cultivate the olive fruit [34,43,44], maturity of 
the olive fruit at harvest [35,39,44–48], and olive oil extraction, processing, storage methods and time 
since harvest [38,45,49–57]. Cooking methods have also been shown to alter phenolic concentrations 
in virgin olive oil [58,59,60]. Finally, research has shown that the analytical method used to quantify 
the concentration of phenolic compounds present in virgin olive oil has an influence on the reported 
concentration  [61]. The factors mentioned above are not discussed in the current paper. For an 
extensive review on the matter, please see the paper by Cicerale and colleagues [62]. Therefore, the 
objective of the current paper was to review the bioavailability of olive oil phenolic compounds and 
the biological activities associated with them. Int. J. Mol. Sci. 2010, 11                 
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2. Bioavailability of Olive Oil Phenolic Compounds 
The bioavailability of a compound refers to the degree in which it is extracted from a food matrix 
and absorbed by the body [63]. The majority of research regarding the bioavailability of olive oil 
phenolic compounds has focused on three major phenolics: hydroxytyrosol, tyrosol, and oleuropein, 
and in general, phenolics from virgin olive oil have been demonstrated to be readily bioavailable.  
Research has shown that the phenolic compounds, hydroxytyrosol and tyrosol are absorbed after 
ingestion in a dose-dependent manner [30,64,65]. Tuck and colleagues [66] demonstrated increased 
bioavailability of hydroxytyrosol and tyrosol when administered as an olive oil solution compared to 
an aqueous solution. The differences in bioavailability have been suggested to be due to the high 
antioxidant content of virgin olive oil compared to water and this high antioxidant content may have 
protected the breakdown of phenolics in the gastrointestinal tract prior to absorption [66]. A further 
study found that absorption of administered ligstroside-aglycone, hydroxytyrosol, tyrosol, and 
oleuropein-aglycone was as high as 55–66% in humans [32]. Finally, oleuropein was demonstrated to 
be somewhat absorbed from isolated perfused rat intestine [67]. The mechanism by which absorption 
occurs with regards to olive oil phenolic compounds remains unclear. However, the different polarities 
of the various phenolics has been postulated to play a role in the absorption of these compounds [32]. 
For instance, the phenolics tyrosol and hydroxytyrosol are polar compounds and their absorption has 
been postulated to occur via passive diffusion [68]. The polar but larger phenolic, oleuropein-glycoside 
may be absorbed via a different mechanism to tyrosol and hydroxytyrosol. It has been proposed that 
oleuropein-glycoside may diffuse through the lipid bilayer of the epithelial cell membrane and be 
absorbed via a glucose transporter. Two additional mechanisms for oleuropein-glycoside absorption 
are potentially via the paracellular route or transcellular passive diffusion  [67]. The phenolics, 
oleuropein and ligstroside-aglycones are less polar and currently there is no data available on their 
mechanism of absorption. Further research is required to substantiate the mechanisms of absorption for 
these phenolics and further investigate the mechanisms for other phenolic compounds.  
Studies examining the quantity of phenolics excreted have also been carried out. A low quantity of 
phenolics present in urine after ingestion would indicate that these phenolics are readily absorbed. 
Excreted phenolics (mainly in the form of hydroxytyrosol and tyrosol) were determined to be 5–16% 
of the total ingested [32]. Excretion of approximately 24% of administered tyrosol was demonstrated 
in a study by Miro-Cases and colleagues  [33]. Finally, Visioli and colleagues  [30] reported the 
excretion of administered hydroxytyrosol and tyrosol to be between 30–60% and 20–22% of the total 
ingested by human subjects, respectively. The above findings demonstrate that humans absorb a 
significant portion (~40–95%, using hydroxytyrosol and tyrosol as proxy) of the dietary olive oil 
phenolic compounds they consume [32]. As most of the data is only based on three phenolics, more 
research is required on the excretion of other key phenolics in virgin olive oil.  
The metabolism of olive oil phenolic compounds is important in determining their availability. If 
phenolics are broken down and converted to other phenolics this may have a notable effect on their 
bioavailability. Phenolic compounds, oleuropein-glycoside and oleuropein and ligstroside-aglycones 
are converted to hydroxytyrosol or tyrosol and excreted in urine [32]. Hydroxytyrosol and tyrosol 
themselves are sometimes conjugated to glucuronic acid and excreted in urine as 
glucuronides [30,32,65,69]. However, further work is needed in this area. Int. J. Mol. Sci. 2010, 11                 
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3. Olive Oil Phenolic Compounds and Health  
Human and animal research have shown that olive oil phenolic compound’s possess important 
biological activities that may exert a preventative effect in regards to the development of chronic 
degenerative diseases. Figure 1 demonstrates the biological activities exerted by olive oil phenolic 
compounds. Table 1 briefly summarizes the findings of several human studies that have investigated 
the biological activities of olive oil phenolic compounds.  
Figure 1. Biological activities of olive oil phenolic compounds (adapted from Cicerale  
et al. [62]). 
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Table 1. Randomized, crossover, controlled, human studies on the effect of olive oil 
phenolic compounds on biomarkers of health (adapted from Cicerale et al. [62]). 
Treatment  Subject 
number 
Olive oil 
phenolic 
concentration 
Study 
design 
Investigated 
biomarker  Key findings  Ref. 
High phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
28 coronary 
heart disease 
subjects 
161 vs.  
14.67 mg/kg 
3 week, 
crossover 
IL-6, C-
reactive 
protein, 
sICAM-1, 
sVCAM-1and 
plasma lipids 
Interleukin-6 and C-reactive 
protein decreased after phenol-
rich olive oil consumption. 
However, no changes in soluble 
intercellular (sICAM-1) and 
vascular adhesion (sVCAM-1) 
molecules and lipid profile were 
observed. 
 [70] 
High phenolic 
concentration vs. 
low phenolic 
concentration-
enriched breakfast 
21 hyper-
cholesterolem
ic subjects 
400 vs.  
80 mg/kg 
Acute dose, 
crossover 
FVIIa and 
PAI-1 
Concentrations of FVIIa 
increased less and PAI-1 activity 
decreased more after the high 
phenolic breakfast than after the 
low phenolic breakfast. 
 [71] 
High phenolic 
concentration vs. 
moderate phenolic 
concentration vs. 
poor phenolic 
concentration 
olive oil 
30 healthy 
subjects 
825 vs. 370 vs. 
0 µmol CAE/kg 
3 week, 
crossover 
Plasma lipids 
and oxLDL 
An increase in phenolic content 
of LDL-C and decrease in oxLDL 
was noted after consumption of 
oil rich in phenolic compounds.  
 [72] 
High phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil vs. corn 
oil 
12 healthy 
subjects 
607 vs. 16 vs.  
0 mg/kg 
Acute dose, 
crossover 
Plasma TXB2, 
plasma LTB4 
and plasma 
antioxidant 
capacity 
Decrease in TXB2 and LTB4 with 
increasing phenolic content of 
olive oil and concomitant increase 
in plasma antioxidant capacity 
with increased phenolic content 
of olive oil. 
 [73] 
High phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
10 healthy 
subjects 
592 vs.  
147 mg/kg 
8 week, 
crossover 
Oxidative 
DNA damage 
and plasma 
antioxidant 
capacity 
A reduction in DNA damage with 
the consumption of a phenol-rich 
olive oil diet was demonstrated. 
No difference was seen in plasma 
antioxidant capacity. 
 [74] 
High phenolic 
concentration vs. 
moderate phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
200 healthy 
subjects 
366 vs. 164 vs. 
2.7 mg/kg 
3 week, 
crossover 
Plasma lipids, 
plasma 
oxLDL, 
plasma F2-
isoprostanes, 
GSH and 
GSSG 
A linear increase in HDL-C was 
observed for low-, medium-, and 
high phenolic olive oil. 
Furthermore, TC to HDL-C ratio 
decreased linearly with the 
increasing phenolic content of the 
olive oil. OxLDL decreased 
linearly with increasing phenolic 
content of the olive oil and TG 
levels decreased for all olive oils. 
Oxidative stress markers 
indicated by GSH and GSSG 
decreased linearly with increasing 
phenolic content.  
 [25] 
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Table 1. Cont. 
High phenolic 
concentration vs. 
moderate phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
12 healthy 
subjects 
366 vs. 164 vs. 
2.7 mg/kg 
Acute dose, 
crossover  
Plasma F2-
isoprostanes 
and plasma 
oxLDL 
All olive oils promoted 
postprandial oxidative stress 
indicated by increased F2-
isoprostanes, however, the degree 
of LDL oxidation decreased as 
the phenolic content in 
administered oil increased. 
 [75] 
High phenolic 
concentration vs. 
low phenolic-
enriched breakfast 
21 hyper-
cholesterolem
ic subjects 
400 vs.  
80 mg/kg 
Acute dose, 
crossover 
Plasma LPO 
and plasma 
F2-
isoprostanes  
Decrease in LPO and F2-
isoprostanes with intake of the 
phenol-enriched breakfast 
compared to low phenol-enriched 
breakfast.  
 [76] 
High phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
22 mild 
dyslipidemic 
subjects 
166 vs. 2 mg/kg  49 day, 
crossover 
Plasma lipids, 
plasma TXB2, 
plasma 
antioxidant 
capacity and 
urinary F2-
isoprostanes 
Plasma TXB2 decreased with 
phenol-rich olive oil 
supplementation. Plasma 
antioxidant capacity increased 
after phenol-rich olive oil 
administration. No effect on 
urinary F2-isoprostanes and 
plasma lipids between phenol-
rich and phenol-poor olive oil 
were observed. 
 [77] 
High phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
43 coronary 
heart disease 
subjects 
161 vs.  
14.67 mg/kg 
3 week, 
crossover 
Plasma 
oxLDL, 
plasma LPO 
and whole 
blood GSH-Px 
Decrease in oxLDL and LPO and 
increase in GSH-Px upon phenol-
rich olive oil consumption. 
 [78] 
High phenolic 
concentration vs. 
moderate phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
30 healthy 
subjects 
150 vs. 68 vs. 0 
mg/kg 
3 week, 
crossover 
Plasma lipids 
and oxLDL 
Sustained consumption of phenol-
rich olive oil was more effective 
in protecting LDL from oxidation 
and in raising HDL-C than olive 
oils with lesser quantities of 
phenolics.  
 [79] 
High phenolic 
concentration vs. 
moderate phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
12 healthy 
subjects 
486 vs. 133 vs. 
10 mg/kg 
4 day, 
crossover 
Plasma lipids, 
plasma 
oxLDL, 
plasma GSH-
Px and urinary 
8-oxo-dG  
 
Short-term consumption of 
phenol-rich olive oil decreased 
plasma oxLDL, urinary 8-oxo-
dG, and increased plasma HDL-C 
and GSH-Px, in a dose-dependent 
manner with the increasing 
phenolic content of the olive oil 
administered.  
 [80] 
High phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
25 healthy 
subjects 
21.6 vs. 
3.0 mg/kg 
3 week, 
crossover 
Plasma 
antioxidant 
capacity and 
oxLDL  
Plasma antioxidant capacity and 
oxLDL did not differ significantly 
between the phenol-rich and 
phenol-poor olive oil. 
 [81] 
High phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
46 health 
subjects 
308 vs.  
43 mg/kg 
3 week, 
crossover 
Plasma lipids, 
plasma oxLDL 
and plasma 
LPO 
 
No effect on plasma lipids, 
oxLDL, and LPO were noted 
between the phenol-rich and 
phenol-poor olive oils. 
 [82] 
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Table 1. Cont. 
Olive oil with 
different phenolic 
concentrations 
6 healthy 
subjects 
1950 vs. 1462.5 
vs. 975 vs.  
487.5 mg/kg 
 
Acute dose, 
cross over 
Urinary F2-
isoprostanes  
A dose-dependent decrease in 
urinary excretion of F2-
isoprostanes was noted upon 
administration of phenol-rich 
olive oil. 
 [29] 
High phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
14 healthy 
subjects 
303 vs.  
0.3 mg/kg 
4 week, 
crossover 
Plasma oxLDL 
and serum 
antioxidant 
capacity 
Increase in plasma antioxidant 
capacity but no change in oxLDL. 
 [83] 
High phenolic 
concentration vs. 
low phenolic 
concentration 
olive oil 
24 peripheral 
vascular 
disease 
subjects 
800 vs. 
 60 mg/kg 
12 week, 
crossover 
Plasma lipids 
and plasma 
oxLDL 
 
A lower oxLDL was noted in 
subjects after administration of 
phenol-rich olive oil. No 
difference in plasma lipids was 
observed. 
 [84] 
4. Olive Oil Phenolic Compounds and Their Beneficial Effect on Plasma Lipoproteins  
Elevated levels of total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) have been 
established as risk factors for atherosclerosis, which is the primary cause of cardiovascular disease 
(CVD). However, on the other hand, elevated high density lipoprotein cholesterol (HDL-C) levels are 
believed to have protective, anti-inflammatory properties [85,86]. Data from a controlled human study 
containing 200 healthy male subjects, found a decrease in TC to HDL-C ratio with increasing phenolic 
content of the virgin olive oil consumed. An increase in HDL-C was also noted with increasing 
phenolic concentration of the oil [25]. Consumption of phenol rich virgin olive oils have resulted in 
increases in circulating HDL-C ranging between 5.1–6.7% in two further human studies  [79,80]. 
Additionally, an earlier study showed a significant decrease in LDL-C after one week of phenol rich 
virgin olive oil consumption  [87]. There are three human studies that showed olive oil phenolic 
compounds had no effect on blood lipid composition [77,82,84]. These studies used people with mild 
dyslipidemia and peripheral vascular disease (as opposed to healthy subjects used in the other studies) 
in two of the three studies and in the third study the authors propose the three week study period may 
not have been long enough to observe a treatment effect. However, it should be noted that in one 
study, four days was ample time to see a change in HDL-C [80].  
Studies involving animals have demonstrated that ingestion of phenol rich virgin olive oil led to 
improvements in blood lipid profile. A study involving rabbits demonstrated a reduction in circulating 
TC and an increase in HDL-C upon virgin olive oil consumption. Furthermore, studies in rats have 
found that the intake of phenol rich virgin olive oil decreases TC, LDL-C and triglyceride (TG) 
levels [88] and substantially increases HDL-C concentrations [89].  
5. Olive Oil Phenolic Compounds and Their Beneficial Effect on Lipid Oxidation  
LDL oxidation (oxLDL) is considered to be a major risk factor for the development of 
atherosclerosis and CVD [90]. Oxidation of LDL causes damage to the vascular wall, stimulating 
macrophage uptake and formation of foam cells, which in turn result in the formation of plaque within 
the arterial wall [78,82,91,92]. Both human and animal in vivo studies have shown that the level at 
which LDL oxidizes, decreases linearly with increasing phenolic concentration Int. J. Mol. Sci. 2010, 11                 
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[25,26,75,78–80,87,93,94]. Two further mechanistic studies, demonstrated that phenolic compounds 
are able to bind to LDL and the authors suggest that this may account for the increase in LDL 
resistance to oxidation [72,95]. Although it is important to note that there have been conflicting results 
from three short term studies suggesting that the phenolic content of the virgin olive oil does not play a 
role in the lowering of oxLDL [81,82,83]. In addition, in vitro studies have found that the phenolic 
compounds extracted from virgin olive oil inhibit the oxidation of LDL-C [40,96–98].  
6. Olive Oil Phenolic Compounds and Their Beneficial Effect on Oxidative DNA Damage 
Oxidative damage to DNA is a precursor for human carcinogenesis [99] and it is well known that 
oxygen radicals continually attack human cells [74]. Unless damage to these cells is counteracted, 
DNA damage may result, and such damage can lead to cancer development [74]. A randomized cross-
over intervention trial has shown that intake of phenol rich virgin olive oil decreases oxidative DNA 
damage by up to 30% compared to a low phenol virgin olive oil  [74]. An additional study also 
demonstrated that after consumption of phenol rich virgin olive oil there was decreased urinary 
excretion of 8-oxo-deoxygyuanosine (8oxodG) a systemic marker of DNA oxidation [99,100].  
In support of these findings, animal studies have also reported that a diet enriched with olive oil 
phenolic compounds has a protective effect against DNA damage [101,102]. In agreement with these 
findings, a recent in vitro study reported that olive oil phenolic compounds showed DNA oxidation 
preventative activity [103].  
7. Olive Oil Phenolic Compounds and Their Beneficial Effect on Additional Markers of 
Oxidation 
Oxidative stress produced by reactive oxygen species (ROS) has been linked to a number of 
diseases such as atherosclerosis, certain cancers and neurodegenerative diseases  [90,104] and is 
considered as a by-product of aerobic metabolism. Goya et al.  [105] treated a sample of human 
hepatoma HepG2 cells with hydroxytyrosol and found that there was a decrease in ROS production. 
Similarly olive oil phenolic compounds have been shown to scavenge ROS under natural and 
chemically simulated oxidative stress conditions [106–108]. A further study by Moreno et al. [109] 
demonstrated that tyrosol modulated ROS production, in murine macrophages [109].  
Total plasma antioxidant activity has also been reported to increase in humans after the ingestion of 
olive oil phenolic compounds [73,74,77]. However, one study did not report an increase in the total 
blood antioxidant capacity [81]. 
Oxidative stress can be indicated by the presence of markers such as F2-isoprostanes, lipid 
peroxides (LPO), oxidized gluthathione (GSSG), reduced gluthathione (GSH) and glutathione 
peroxidase (GSH-Px). F2-isoprostanes are a result of the free radical induced peroxidation of 
arachidonic acid. LPO is more than likely a by-product of the oxidation of fatty acids  [76] and 
depletion of the protective GSH precedes lipid oxidation and atherogenesis in vivo [110].  
Human studies have shown beneficial effects of olive oil phenolic compounds on these 
aforementioned markers of oxidative stress. A randomized cross over study found the intake of a olive 
oil phenolic-enriched breakfast significantly lowered F2-isoprostane levels compared to a low 
phenolic-enriched breakfast  [76]. Visioli and colleagues  [29] demonstrated that consumption of a Int. J. Mol. Sci. 2010, 11                 
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phenolic-rich virgin olive oil was associated with a significant decrease in urinary excretion of   
F2-isoprostanes. Another human study did not find an effect of olive oil phenolics on F2-isoprostane 
levels, this may be possibly due to the considerably low phenolic content of the oil administered  
(166 mg/kg) [77] compared to a phenolic content up 1950 mg/kg in the Visioli et al. study [29]. An 
animal study also found that administration of hydroxytyrosol-containing olive oil waste water to rats 
exposed to cigarette smoke, lowered F2-isoprostane levels significantly (p < 0.05) [64].  
Covas and colleagues  [25] found that phenol-rich virgin olive oil beneficially modulated the 
balance between GSH and GSSG, while Weinbrenner and colleagues [80] found an increase in GSH-
Px after phenol-rich virgin olive oil administration in human subjects. Moreover, a decrease in LPO 
after olive oil phenolic administration has been noted. More recently, olive oil phenolic compounds 
sourced from olive mill waste water were found to increase GSH concentrations in human blood [111]. 
Two further studies have also shown that olive oil phenolic compounds reduce oxidative damage to 
both red blood cells and renal cells [108,112].  
8. Olive Oil Phenolic Compounds and Their Beneficial Effect on Markers of Inflammation 
Elevated concentrations of inflammation markers in serum are associated with increased 
cardiovascular risk [113]. Plasma thromboxane B2 (TXB2) and leukotriene B4 (LTB4) are known pro-
inflammatory agents. TXB2 has the ability to increase blood platelet aggregation and LTB4 has a 
chemostactic effect on neutrophils, directing the cells to damaged tissue [73,114]. These inflammatory 
agents are known to produce the pain, redness and swelling associated with inflammation  [115]. 
Bogani and colleagues  [73] found a decrease in TXB2 and LTB4  concentrations with increasing 
phenolic concentration of the olive oil. These results were also in accordance with previous 
investigations [77,80,116].  
The inflammatory markers, Interleukin-6 (IL-6) and C-reactive protein (CRP) have been shown to 
be predictors for CVD also [70]. IL-6 is a pro-inflammatory agent that stimulates inflammation in 
response to trauma and CRP generally rises when inflammation is present [70]. Fito and colleagues [70] 
found that consumption of olive oil phenolic compounds from a daily dose of virgin olive oil 
decreased the circulating concentrations of both IL-6 and CRP in 28 stable coronary heart patients.  
In vitro study findings also support the anti-inflammatory capacity of olive oil phenolic compounds. 
Olive oil phenolics have been found to decrease arachidonic acid release and arachidonic acid 
metabolite synthesis in vitro and both of these are involved in the inflammatory process [109]. The 
olive oil phenolic compound, oleocanthal was shown to inhibit cyclooxygenase-1 (COX-1) and 
cyclooxygenase-2 (COX-2) activity (both involved in the inflammatory process) in the same way as 
the anti-inflammatory drug, ibuprofen does [117]. Inhibition of COX enzymes results in the reduction 
of arachidonate to the eicosanoids, prostaglandins and thromboxane, in the inflammatory 
pathway [114,118]. 
9. Olive Oil Phenolic Compounds and Their Beneficial Effect on Platelet Function 
Blood platelets have been demonstrated to play a role in CVD and atherosclerosis development. 
Continual damage to the vascular epithelium results in the development of lesions and these lesions 
stimulate endothelial adhesion molecule expression, platelet activity and aggregation  [119,120]. Int. J. Mol. Sci. 2010, 11                 
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Circulating monocytes are attracted by these particular molecules and adhere to the endothelium and 
differentiate into macrophages, which in turn scavenge LDL and triglyceride (TG) rich lipoproteins, 
becoming foam cells and forming fatty streaks [121].  
Olive oil phenolic compounds have been shown to inhibit endothelial adhesion molecule expression 
upon incubation with human umbilical vein endothelial cells [27]. They also have been demonstrated 
to inhibit human platelet activity in vitro [122]. The phenolic compound, hydroxytyrosol has been 
noted to completely inhibit platelet aggregation in human blood (in vitro) in the range of   
100–400 μM [123]. A more recent investigation, demonstrated that a number of olive oil phenolic 
compounds (such as oleuropein aglycone and luteolin) also were potent inhibitors of platelet 
aggregation [124]. Virgin olive oil containing a high content (400 mg/kg) of phenolic compounds has 
been demonstrated to also decrease plasminogen activator inhibitor-1 (PAI-1) and factor VII (FVII). 
Both PAI-1 and FVII are pro-coagulant factors that have been linked to the development of coronary 
heart disease (CHD)  [71]. Furthermore, olive oil phenolics have been shown to decrease 
homocysteine, which has been linked to increased adhesiveness of the endothelium [125].  
10. Olive Oil Phenolic Compounds and Their Beneficial Effect on Cellular Function 
Cell proliferation and suppressed cell death are underlying factors for tumor formation and 
progression [126]. Research to date has shown that the olive oil phenolic, hydroxytyrosol inhibits cell 
proliferation in human promyelocytic HL60 leukemia cells and in human colon cancer   
lines [127–129]. Hashim and colleagues [130] demonstrated a dose-related inhibition of colon cancer 
cell invasion by olive oil phenolic compounds. Also, hydroxytyrosol has been found to exert strong 
anti-proliferative effects against human colon adenocarcinoma cells  [131]. More recently, research 
using MCF-7 and SKBR3 breast cancer cells showed that phenolic compounds inhibit cell growth in 
these cell lines in a dose dependent manner and reduce expression of the HER2 oncogene which plays 
a integral role in malignant transformation, tumorigenesis, and metastasis [132–134]. Furthermore, 
oleuropein and hydroxytyrosol have been show to induce cell death of MCF-7 human breast cancer 
cells [135]. Olive oil phenolics have also been found to improve cell integrity and viability in CaCo2 
cells [128,136]. 
The olive oil phenolic compound, oleocanthal has been implicated in the reduced incidence of 
Alzheimer’s disease in Mediterranean populations via two mechanisms. First, in Alzheimer’s disease a 
microtubule-associated protein (Tau) involved in the promotion of microtubule assembly and stability 
begin to aggregate into neurofibrillary tangles. Li and colleagues [137] demonstrated that oleocanthal 
inhibits tau aggregation. Second, beta-amyloid (Aβ) oligomers (also referred to as ADDLs) have also 
been suggested to be involved in the development of Alzheimer’s disease. These ADDLs are believed 
to bind to postsynaptic sites and cause synaptic and neuronal loss. Pitt and colleagues [138] have 
demonstrated that oleocanthal has the capacity to alter the oligomerization state of ADDLs whilst 
protecting neurons from the synaptopathological effects of ADDLs. Thus, oleocanthal protects neurons 
from ADDL induced synaptic deterioration and additionally promotes the antibody clearance of 
ADDLs [138]. A further study demonstrated the neuro-protection of hydroxytyrosol in rat brains. In 
this study it was found that hydroxytyrosol reduced lactate dehydrogenase activity which has been 
closely related with a reduction in brain lipid peroxidation [139].  Int. J. Mol. Sci. 2010, 11                 
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11. Olive Oil Phenolic Compounds and Their Beneficial Effect on Microbial Activity 
In vitro research has shown that olive oil phenolic compounds have antimicrobial properties. 
Particularly, the phenolic compounds, oleuropein, hydroxytyrosol and tyrosol have demonstrated 
potent antimicrobial activity against several strains of bacteria responsible for intestinal and 
respiratory infections  [140]. Romero and colleagues  [141] found that the dialdehydic form of 
decarboxymethyl ligstroside is not hydrolyzed in the stomach and therefore aids in inhibiting the 
growth of Helicobacter pylori bacteria. Helicobacter pylori bacteria are linked to the development of 
peptic ulcers and some types of gastric cancer. Hydroxytyrosol and oleuropein have also been shown 
to be cytotoxic to a large number of bacterial strains [142].  
12. Olive Oil Phenolic Compounds and Their Beneficial Effect on Bone 
One study to date has investigated the effect of olive oil phenolic compounds on bone [143]. In this 
study, both tyrosol and hydroxytyrosol increased bone formation in rats significantly. Further studies 
are now required to substantiate these findings.  
13. Conclusions 
In conclusion, olive oil phenolic compounds are highly bioavailable in humans. The high 
bioavailability of such compounds lends support to evidence that these phenolic components exert 
beneficial effects on health. Although, the beneficial health effects of virgin olive oil ingestion are well 
known, it is only recent that that the biological properties of olive oil phenolic compounds have been 
investigated. In experimental studies (in vivo and in vitro), olive oil phenolic compounds have been 
shown to beneficially alter lipid composition, platelet and cellular function, microbial activity and 
bone formation, as well as reduce oxidative damage and inflammation. The modes of action detailed in 
the paper, may explain the low rate of diet-related diseases amongst populations residing in the 
Mediterranean region. For example, the anti-atherogenic effects associated with the ingestion of virgin 
olive oil may explain the low rate of cardiovascular disease in Mediterranean populations. Since DNA 
oxidative damage is a mechanism underlying cancer development, the protective effects of olive oil 
phenolic compounds may explain some of the differences in cancer incidence between Mediterranean 
populations and other populations in the world. The anti-inflammatory effects that arise from the 
ingestion of olive oil phenolic compounds have been shown to provide protection against diseases 
marked by an inflammatory component. This may, along with other modes of action, partly explain the 
low rate of CVD mortality and certain types of cancer in populations residing in the Mediterranean. 
Olive oil phenolic compounds may also be useful in the treatment of some infectious diseases. Finally, 
although more studies are required, findings demonstrating the beneficial effects of olive oil phenolics 
in relation to bone health, may aid in partly explaining the low incidence of osteoporosis in 
populations residing in the Mediterranean area. These biological properties may have a significant 
impact on population health through the reduction in incidence of chronic degenerative disease 
development.  Int. J. Mol. Sci. 2010, 11                 
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